The postoperative neutrophil-to-lymphocyte ratio and changes in this ratio predict survival after the complete resection of stage I non-small cell lung cancer

OncoTargets and Therapy

Volumn 9, Issue , 2016, Pages 6529-6537

  Jin, Feng ^a,b   Han, Anqin ^b   Shi, Fang ^b   Kong, Li ^b   Yu, Jinming ^b  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

^b SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Neutrophil to lymphocyte ratio; Non small cell lung cancer; Prognosis; Stage I; Surgery

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX;

ADULT; AGE; AGED; ARTICLE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPHIL LYMPHOCYTE RATIO; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PLATELET LYMPHOCYTE RATIO; POSTOPERATIVE PERIOD; PREDICTION; PREOPERATIVE PERIOD; RETROSPECTIVE STUDY; RISK ASSESSMENT; SMOKING;

EID: 84993995783     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S117290     Document Type: Article

References (37)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.
2. Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62(4):220–241.
3. Brock MV, Hooker CM, Ota-Machida E, et al. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med. 2008;358(11): 1118–1128.
4. Gu XB, Tian T, Tian XJ, Zhang XJ. Prognostic significance of neutrophil-to-lymphocyte ratio in non-small cell lung cancer: a meta-analysis. Sci Rep. 2015;5:12493.
5. Zhang T, Jiang Y, Qu X, Shen H, Liu Q, Du J. Evaluation of preoperative hematologic markers as prognostic factors and establishment of novel risk stratification in resected pN0 non-small-cell lung cancer. PLoS One. 2014;9(10):e111494.
6. Pinato DJ, Shiner RJ, Seckl MJ, Stebbing J, Sharma R, Mauri FA. Prognostic performance of inflammation-based prognostic indices in primary operable non-small cell lung cancer. Br J Cancer. 2014;110(8): 1930–1935.
7. Takahashi Y, Horio H, Hato T, et al. Prognostic significance of preoperative neutrophil-lymphocyte ratios in patients with stage 1 non-small cell lung cancer after complete resection. Ann Surg Oncol. 2015;22(suppl 3): 1324–1331.
8. Zhang H, Xia H, Zhang L, Zhang B, Yue D, Wang C. Clinical significance of preoperative neutrophil-lymphocyte vs platelet-lymphocyte ratio in primary operable patients with non-small cell lung cancer. Am J Surg. 2015;210(3):526–535.
9. Liao Y, Ni Y, He R, et al. Clinical implications of fibroblast activation protein-alpha in non-small cell lung cancer after curative resection: a new predictor for prognosis. J Cancer Res Clin Oncol. 2013;139(9): 1523–1528.
10. Miyazaki T, Yamasaki N, Tsuchiya T, et al. Inflammation-based scoring is a useful prognostic predictor of pulmonary resection for elderly patients with clinical stage I non-small-cell lung cancer. Eur J Cardiothorac Surg. 2015;47(4):e140–e145.
11. Li C, Wen TF, Yan LN, et al. Postoperative neutrophil-to-lymphocyte ratio plus platelet-to-lymphocyte ratio predicts the outcomes of hepatocellular carcinoma. J Surg Res. 2015; 198(1):73–79.
12. Shibutani M, Maeda K, Nagahara H, et al. The prognostic significance of a postoperative systemic inflammatory response in patients with colorectal cancer. World J Surg Oncol. 2015;13: 194.
13. Kang M, Jeong CW, Kwak C, Kim HH, Ku JH. The prognostic significance of the early postoperative neutrophil-to-lymphocyte ratio in patients with urothelial carcinoma of the bladder undergoing radical cystectomy. Ann Surg Oncol. 2016;23(1):335–342.
14. Peng W, Li C, Wen TF, et al. Neutrophil to lymphocyte ratio changes predict small hepatocellular carcinoma survival. J Surg Res. 2014;192(2):402–408.
15. Dan J, Zhang Y, Peng Z, et al. Postoperative neutrophil-to-lymphocyte ratio change predicts survival of patients with small hepatocellular carcinoma undergoing radiofrequency ablation. PLoS One. 2013;8(3):e58184.
16. Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest. 2009;136(1):260–271.
17. Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y. The new World Health Organization classification of lung tumours. Eur Respir J. 2001;18(6):1059–1068.
18. Takahashi Y, Kawamura M, Hato T, Harada M, Matsutani N, Horio H. Neutrophil-lymphocyte ratio as a prognostic marker for lung adenocar-cinoma after complete resection. World J Surg. 2016;40(2):365–372.
19. Hu P, Shen H, Wang G, Zhang P, Liu Q, Du J. Prognostic significance of systemic inflammation-based lymphocyte- monocyte ratio in patients with lung cancer: based on a large cohort study. PLoS One. 2014;9(9): e108062.
20. Kos M, Hocazade C, Kos FT, et al. Prognostic role of pretreatment platelet/lymphocyte ratio in patients with non-small cell lung cancer. Wien Klin Wochenschr. 2016;128(17–18):635–640.
21. Zhao QT, Yang Y, Xu S, et al. Prognostic role of neutrophil to lymphocyte ratio in lung cancers: a meta-analysis including 7,054 patients. Onco Targets Ther. 2015;8:2731–2738.
22. Yin Y, Wang J, Wang X, et al. Prognostic value of the neutrophil to lymphocyte ratio in lung cancer: a meta-analysis. Clinics (Sao Paulo). 2015;70(7):524–530.
23. Kundu JK, Surh YJ. Inflammation: gearing the journey to cancer. Mutat Res. 2008;659(1–2):15–30.
24. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–899.
25. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331(6024):1565–1570.
26. Vendramini-Costa DB, Carvalho JE. Molecular link mechanisms between inflammation and cancer. Curr Pharm Des. 2012;18(26):3831–3852.
27. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immu-nosurveillance and immunoediting. Immunity. 2004;21(2):137–148.
28. Hiraoka K, Miyamoto M, Cho Y, et al. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer. 2006;94(2):275–280.
29. Applegate KG, Balch CM, Pellis NR. In vitro migration of lymphocytes through collagen matrix: arrested locomotion in tumor-infiltrating lymphocytes. Cancer Res. 1990;50(22):7153–7158.
30. Ratner S, Heppner GH. Mechanisms of lymphocyte traffic in neoplasia. Anticancer Res. 1986;6(3 pt B):475–482.
31. Gutkin DW, Shurin MR. Clinical evaluation of systemic and local immune responses in cancer: time for integration. Cancer Immunol Immunother. 2014;63(1):45–57.
32. Galon J, Pages F, Marincola FM, et al. The immune score as a new possible approach for the classification of cancer. J Transl Med. 2012; 10:1.
33. Lin GN, Peng JW, Xiao JJ, Liu DY, Xia ZJ. Prognostic impact of circulating monocytes and lymphocyte-to-monocyte ratio on previously untreated metastatic non-small cell lung cancer patients receiving platinum-based doublet. Med Oncol. 2014;31(7):70.
34. Song YJ, Wang LX, Hong YQ, et al. Lymphocyte to monocyte ratio is associated with response to first-line platinum-based chemotherapy and prognosis of early-stage non-small cell lung cancer patients. Tumour Biol. 2016;37(4):5285–5293.
35. Choi JE, Villarreal J, Lasala J, et al. Perioperative neutrophil:lymphocyte ratio and postoperative NSAID use as predictors of survival after lung cancer surgery: a retrospective study. Cancer Med. 2015;4(6):825–833.
36. Medina Fernandez FJ, Munoz-Casares FC, Arjona-Sanchez A, et al. Postoperative time course and utility of inflammatory markers in patients with ovarian peritoneal carcinomatosis treated with neoadjuvant chemotherapy, cytoreductive surgery, and HIPEC. Ann Surg Oncol. 2015;22(4):1332–1340.
37. Josa V, Krzystanek M, Eklund AC, et al. Relationship of postoperative thrombocytosis and survival of patients with colorectal cancer. Int J Surg. 2015;18:1–6.